151 related articles for article (PubMed ID: 37964494)
1. The efficacy of sorafenib against hepatocellular carcinoma is enhanced by 5-aza-mediated inhibition of ID1 promoter methylation.
Meng J; Li S; Niu ZQ; Bao ZQ; Niu LL
FEBS Open Bio; 2024 Jan; 14(1):127-137. PubMed ID: 37964494
[TBL] [Abstract][Full Text] [Related]
2. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
[TBL] [Abstract][Full Text] [Related]
3. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
4. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
5. Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine.
Fan H; Zhao ZJ; Cheng YC; Shan YF; Lu ZH; Zhang JQ; Xie W
Chin Med J (Engl); 2007 Sep; 120(18):1626-31. PubMed ID: 17908484
[TBL] [Abstract][Full Text] [Related]
6. Id1 is down-regulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16INK4a in hepatoma cells.
Ushio K; Hashimoto T; Kitamura N; Tanaka T
Mol Cancer Res; 2009 Jul; 7(7):1179-88. PubMed ID: 19567783
[TBL] [Abstract][Full Text] [Related]
7. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
[TBL] [Abstract][Full Text] [Related]
8. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance.
Zhou T; Li S; Xiang D; Liu J; Sun W; Cui X; Ning B; Li X; Cheng Z; Jiang W; Zhang C; Liang X; Li L; Cheng X; Hui L; Wang H; Ding J
Signal Transduct Target Ther; 2020 Dec; 5(1):296. PubMed ID: 33361765
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
10. Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma.
Hirasawa Y; Arai M; Imazeki F; Tada M; Mikata R; Fukai K; Miyazaki M; Ochiai T; Saisho H; Yokosuka O
Oncology; 2006; 71(1-2):77-85. PubMed ID: 17341888
[TBL] [Abstract][Full Text] [Related]
11. BMP9-ID1 Pathway Attenuates N
Chen H; Zhang M; Li J; Liu M; Cao D; Li YY; Yamashita T; Nio K; Tang H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256056
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.
Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L
J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482
[TBL] [Abstract][Full Text] [Related]
13. 5-Aza-2<-deoxycytidine induces hepatoma cell apoptosis via enhancing methionine adenosyltransferase 1A expression and inducing S-adenosylmethionine production.
Liu WJ; Ren JG; Li T; Yu GZ; Zhang J; Li CS; Liu ZS; Liu QY
Asian Pac J Cancer Prev; 2013; 14(11):6433-8. PubMed ID: 24377546
[TBL] [Abstract][Full Text] [Related]
14. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma.
Chen H; Nio K; Yamashita T; Okada H; Li R; Suda T; Li Y; Doan PTB; Seki A; Nakagawa H; Toyama T; Terashima T; Iida N; Shimakami T; Takatori H; Kawaguchi K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Mol Oncol; 2021 Aug; 15(8):2203-2218. PubMed ID: 33834612
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.
Sharma BK; Kolhe R; Black SM; Keller JR; Mivechi NF; Satyanarayana A
FASEB J; 2016 Jan; 30(1):262-75. PubMed ID: 26330493
[TBL] [Abstract][Full Text] [Related]
16. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
[TBL] [Abstract][Full Text] [Related]
17. Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
Yan Q; Zhang ZF; Chen XP; Gutmann DH; Xiong M; Xiao ZY; Huang ZY
Int J Oncol; 2008 May; 32(5):1057-63. PubMed ID: 18425332
[TBL] [Abstract][Full Text] [Related]
18. BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.
Chen H; Nio K; Tang H; Yamashita T; Okada H; Li Y; Doan PTB; Li R; Lv J; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163396
[TBL] [Abstract][Full Text] [Related]
19. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
20. DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression.
Borghesan M; Fusilli C; Rappa F; Panebianco C; Rizzo G; Oben JA; Mazzoccoli G; Faulkes C; Pata I; Agodi A; Rezaee F; Minogue S; Warren A; Peterson A; Sedivy JM; Douet J; Buschbeck M; Cappello F; Mazza T; Pazienza V; Vinciguerra M
Cancer Res; 2016 Feb; 76(3):594-606. PubMed ID: 26772755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
